BioStem Technologies, Inc. Insider Transaction Report

On September 15, 2026, Kenneth Howard Warrington Jr., a director at BioStem Technologies, Inc., acquired 1,694 shares of common stock through the vesting of restricted stock units. These units, granted on September 15, 2024, vest quarterly over three years. Following this transaction, Warrington Jr. holds 33,928 shares of common stock directly. Additionally, he holds 7,462 options to buy common stock, with an exercise price of $1.80, and 6,773 restricted stock units that represent a contingent right to receive one share of common stock each upon vesting. The options are fully vested and exercisable, with an expiration date of March 29, 2032.